Abstract
Sold under the brand name of Garamycin, gentamicin (GM) is an antibiotic in the category of aminoglycoside, that although does have many antibacterial properties, owing to several side effects, its consumption is confined. The current study is aimed at gauging the protective influences of human umbilical cord blood serum (hUCBS) on nephrotoxicity which is induced by GM. In this regard, in the present experimental design, twenty-eight male Wistar rats with the weights of 220 ± 20 g were categorized randomly into 4 groups of seven. The groups included GM (100 mg/kg), control as well as hUCBS at doses of one and two percent together with GM (100 mg/kg) for ten days in an intraperitoneal manner. Blood sampling was collected from the heart directly 24 h after the final injection for obtaining blood serum; the parameters of C-reactive protein (CRP), total oxidant status (TOS), interleukin (IL)-6, lactate dehydrogenase (LDH), total antioxidant capacity (TAC), creatinine (Cr), blood urea nitrogen (BUN), blood serum glutathione (GSH) were gauged in blood serum samples to evaluate renal function. Moreover, for histology, an examination of kidney tissue was performed. In comparison to those of the GM group, in the treatment group, hUCBS significantly decreased the levels of BUN, Cr, LDH, TOS, IL-6, and the CRP levels, and significantly increased the TAC and GSH levels. It was revealed that the treatment of the animals with hUCBS culminates in the reduction of GM’ toxic impacts on the kidney.
Acknowledgements
The authors extend their sincere appreciation to Dr. Morteza Zarrabi at the Royan Stem Cell Technology and Cord Blood Bank of Tehran for providing human umbilical cord blood serum to be used in the present study.
Ethical approval
All experiments in this study regarding the animal rights and conservation were performed according to the standard ethical guidelines (European Communities Directive 2010/63/EU) and were endorsed by the University of Bu-Ali Sina’s Local Ethics Committee (permit No.: IR.BASU.REC.1398.035).
Disclosure statement
The authors wish to declare that they have no conflict of interest.
Data availability statement
The data that support the findings of the research are available and can be attained from the corresponding author, upon reasonable request.